FDA Grants Fast Track Designation to MavriX Bio's MVX-220 Gene Therapy for Angelman Syndrome
Key Insights
The FDA has granted Fast (search) Track designation to MVX-220 (search), an investigational adeno-associated virus (AAV) gene therapy developed by MavriX Bio (search) for treating Angelman syndrome (search).
MVX-220 (search) is designed to restore functional expression of the UBE3A (search) gene in neurons, addressing the underlying genetic cause of Angelman syndrome (search).
The designation enables accelerated development and closer FDA collaboration as MavriX Bio (search) prepares to initiate ASCEND-AS, a Phase 1/2 first-in-human clinical study.
The U.S. Food and Drug Administration has granted Fast (search) Track designation to MVX-220 (search), an investigational adeno-associated virus (AAV) gene therapy developed by MavriX Bio (search) for treating Angelman syndrome (search). The designation is intended to facilitate development and expedite review of drugs addressing serious conditions with significant unmet medical needs.
Addressing a Critical Unmet Need
Angelman syndrome (search) is a rare, non-degenerative, monogenic neurological disorder that affects approximately 1 in 12,000 to 1 in 20,000 individuals. The condition is characterized by severe developmental delay, lack of verbal speech, sleep disturbances, seizures, and motor and balance impairments. The syndrome is caused by the loss of function of the UBE3A (search) gene in neurons, and currently has no approved treatments available.
"The FDA's decision to grant Fast (search) Track designation for MVX-220 (search) reflects the urgent need for therapies for individuals living with Angelman syndrome (search)," said Allyson Berent, DVM, DACVIM, Chief Development Officer of MavriX Bio (search). "This designation highlights the promise MVX-220 holds as a potential treatment for AS, and importantly, enables closer collaboration with the FDA and an accelerated path forward."
Gene Therapy Approach
MVX-220 (search) is an investigational gene therapy designed to restore functional expression of the UBE3A (search) gene in neurons using targeted AAV delivery, directly addressing the underlying genetic cause of Angelman syndrome (search). The therapy was developed at the University of Pennsylvania with full support from the Foundation for Angelman Syndrome Therapeutics (FAST (search)), which funded both the development and nonclinical research activities.
The program was subsequently licensed to MavriX Bio (search), a portfolio company of FAST (search)'s drug development accelerator AS2Bio (search), to enable clinical translation in collaboration with GEMMABio (search), a therapeutics company focused on developing transformative gene therapies.
Clinical Development Progress
In May 2025, the FDA cleared the Investigational New Drug (IND) application for MVX-220 (search). MavriX Bio (search) is now preparing to initiate ASCEND-AS, a Phase 1/2 first-in-human study that will evaluate the safety, tolerability, and efficacy of MVX-220 in adult and pediatric individuals living with various genotypes of Angelman syndrome (search), including deletion, uniparental disomy (UPD) and imprinting center defects (ID).
"GEMMABio (search) has been deeply honored to support MavriX Bio (search) on the MVX-220 (search) development program. With Fast (search) Track status, this program gains crucial momentum — it means the team can engage more closely with regulators and accelerate development milestones," said James M. Wilson, MD, PhD, Chief Executive Officer at GEMMA Biotherapeutics. "For the Angelman syndrome (search) community, Fast Track designation opens up a path toward bringing gene-targeted therapies to patients sooner."
Community Engagement
MavriX Bio (search) will join the Foundation for Angelman Syndrome (search) Therapeutics (FAST (search)) and the Angelman Syndrome Foundation (ASF) for an Angelman Community Webinar on Thursday, October 9, 2025, at 1:00 p.m. EST. The webinar will provide a summary of the trial design, enrollment criteria, and study procedures for the ASCEND-AS study, with opportunities for community members to submit questions.
The Fast (search) Track designation provides opportunities for more frequent communication with the FDA during drug development and may allow for priority review if specific criteria are met, representing a significant milestone for the Angelman syndrome (search) community in their pursuit of effective treatments.